UCB CEO warns Europe it can't declare biopharma a strategic industry and not pay up
This article was originally published in Scrip
European governments can't have it both ways: declaring on the one hand that biopharma is a strategic industry and then on the other shying away from paying to give their citizens access to innovative medicines. This was the stark warning from Roch Doliveux, CEO of UCB.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.